Thursday, June 15, 2017
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128
	
Persons who wish to address the P&T Committee may contact Bryan S. Larson at (bslarson@utah.gov) prior to the meeting, or sign up to provide comments at the meeting.  Public comments will be limited to 3 minutes per speaker or organization due to time constraints.

1)	Call to order - Clinton Sheffield, MD, Chair
a)	Announce Quorum

2)	Welcome and Introductions - Clinton Sheffield, MD, Chair
a)	Review and Approval of Minutes
b)	Housekeeping

3)	DUR Board Update - Robyn Seely, PharmD

4)	June Review
a)	Parathyroid Hormone Analogs - Valerie Gonzales, PharmD
i)	Abaloparatide, Teriparatide, Parathyroid Hormone
b)	Public Comment
i)	Shire - Monica Saleh
c)	Other States Report - Bryan S. Larson, PharmD
d)	Committee Discussion/Questions 
e)	Committee Action

5)	No meeting in July. Next Meeting August 17, 2017 Long-Acting Anticholinergic, Beta-2 Agonist Combination Inhalers

6)	Adjourned - Clinton Sheffield, MD, Chair

The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to:

Dr. Joanne LaFleur
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.	

Tentative 2017 Pharmacy & Therapeutics Committee Schedule
Month	Topic	Agents
20 Jul 2017*	No meeting	No meeting

17 Aug 2017*	Long-Acting Anticholinergic, Beta-2 Agonist Combination Inhalers	Glycopyrrolate/Formoterol, Umeclidinium/Vilanterol, Tiotropium/Olodaterol, Indacaterol/Glycopyrrolate

21 Sep 2017*	Long-Acting Beta-2 Agonist & Glucocorticoid Combinations	Budesonide/Formoterol, Fluticasone/Salmeterol, Fluticasone/Vilanterol, Mometasone/ Formoterol

19 Oct 2017*	Anthelmintics	Albendazole, Diethylcarbamazine, Ivermectin, Mebendazole, Praziquantel, Pyrantel Pamoate

16 Nov 2017*	Vitamin D analogs	Alendronate/Cholecalciferol, Alfacalcidol, Calcifediol, Calcipotriene, Calcipotriene/Betamethasone, Calcitriol, Cholecalciferol, Doxercalciferol, Paricalcitol

21 Dec 2017*	Antiplatelet Agents (1)	TBD

18 Jan 2018*	Antiplatelet Agents (2)	TBD

15 Feb 2018*	Bisphosphonates	TBD

*Please note: all topics are tentative and subject to change.